BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Evofem Biosciences, Inc. EVFM
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$20.2M
▲ 4.2% vs FY2024
EPS · FY25
$0.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
1.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 20.2M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
USD 0.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin16.7%
Net margin1.9%
Return on assets1.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+114.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+6.2%
+114.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 20.3M
total assets, end of FY2025
Total assetsUSD 20.3M
EquityUSD -74.3M
CashUSD 578,000.00
Gross debtUSD 147,000.00
Net debtUSD -431,000.00
Current ratio0.18×
The company holds more cash than debt.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
0.0
−0.0
−0.0
−0.1
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
0.0
−0.0
0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.00
−0.11
0.05
−167.42
−23.63
−2.12
−1.99
−5.74
−55.78
−5.66
−18.91
−5.36
−29.33
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
−0
·
·
·
·
·
ROE %
·
·
·
·
·
−1675.9
·
·
·
·
−96.9
−252.9
·
Shares out B
0.13
0.11
0.02
0.00
0.01
0.08
0.05
0.03
0.00
0.00
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
36 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed